CALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indications
New formulation can be co-administered with gastric acid-reducing agents Tablet offers efficacy, safety and consistent dosing compared to current capsule WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s new tablet formulation of CALQUENCE® (acalabrutinib) has been approved in the US for all current indications, including adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and for patients with … [Read more…]